Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
暂无分享，去创建一个
A. Ravaud | M. Nikolski | T. Barnetche | M. Beylot-Barry | S. Prey | A. Tison | E. Forcade | J. Seneschal | T. Schaeverbeke | M. Kostine | C. Dutriaux | A. Barré | L. Rouxel | R. Veillon | L. Dousset | C. Domblides | B. Sionneau | A. Daste | C. Vergnenègre | E. Mauric | M. Gross‐Goupil | M. Beylot‐Barry | M. Gross-Goupil | E. Forcade | R. Veillon